Implantable contraception

REFERENCES

• Ortho Pharmaceutical Corporation Annual Birth Control Study 1994
   Google Scholar
• Segal SJ, Croxatto HB. Single administration of hormones for long term control of reproductive function. Presented at XXIII Meeting of American Fertility Society, Washington DC, 1967
   Google Scholar
• World Health Organization. Facts about an implantable contraceptive. Bull WHO 1985; 63: 485–94
   PubMed Web of Science ®Google Scholar
• Frank ML, Poindexter AN, Cornin LM, et al. One-year experience with subdermal contraceptive implants in the United States. Contraception 1993; 48: 229–43
   PubMed Web of Science ®Google Scholar
• Robertson DN, Sivin I, Nash H, et al. Release rates of levonorgestrel from silastic capsules, homogenous rods and covered rods in humans. Contraception 1983; 27: 483–95
   PubMed Web of Science ®Google Scholar
• Anon. In Waldman S, ed. Norplant® Levonorgestrel Implants: A Summary of Scientific Data. New York, USA: The Population Council, 1990; 1–32
   Google Scholar
• Fotherby K. Levonorgestrel. Clinical pharmacokinetics. Clin Pharmacokinet 1995; 28: 203–15
   PubMed Web of Science ®Google Scholar
• Ladipo O, Coutinho EM. Contraceptive implants. Curr Opin Obstet Gynecol 1994; 6: 564–9
   PubMed Web of Science ®Google Scholar
• Affandi B. Implantable contraceptives. In Runnebaum B, Rabe T, Kiesel L, eds. Female Contraception and Male Fertility Regulation. Carnforth, UK: Parthenon, 1992; 123–30
   Google Scholar
• Croxatto HB, Díaz S, Sivin I. Contraceptive implants. Ann N Y Acad Sci 1991; 626: 22–9
   PubMedGoogle Scholar
• Peralta O, Díaz S, Croxatto H. Subdermal contraceptive implants. J Steroid Biochem Mol Biol 1995; 53: 1–6
   Web of Science ®Google Scholar
• Huber J. Pharmacokinetics of Implanon®: an integrated analysis. Contraception 1998; 58(Suppl 6): 85S–90S
   PubMed Web of Science ®Google Scholar
• Coutinho EM. One year contraception with a single subdermal implant containing nomegestrol acetate (Uniplant). Contraception 1993; 47: 97–105
   PubMed Web of Science ®Google Scholar
• Darney PD, Cook CE, Klaisle CM, et al. Evaluation of a 1-year levonorgestrel-releasing contraceptive implant: side effects, release rates and biodegradability. Fertil Steril 1992; 58: 137–43
   PubMed Web of Science ®Google Scholar
• Olsson SE, Odlind V, Johansson E. Clinical results with subcutaneous implants containing 3-keto desogestrel. Contraception 1990; 42: 1–11
   PubMed Web of Science ®Google Scholar
• Díaz S, Pavez M, Moo-Young AJ, et al. Clinical trial with 3-keto-desogestrel subdermal implants. Contraception 1991; 44: 393–408
   PubMed Web of Science ®Google Scholar
• Mäkäräinen L, van Beek A, Tuomivaara L, et al. Ovarian function during the use of a single contraceptive implant: Implanon compared with Norplant. Fertil Steril 1998; 69: 714–21
   PubMed Web of Science ®Google Scholar
• Li XF, Davies GC, Newton J. A review of the effects of long-acting progestogen-only contraceptives on ovarian activity. Adv Contracept 1992; 8: 1–19
   PubMedGoogle Scholar
• Segal SJ, Alvarez-Sanchez F, Brache V, et al. Norplant® implants: the mechanism of contraceptive action. Fertil Steril 1991; 56: 273–7
   PubMed Web of Science ®Google Scholar
• Brache V, Faundes A, Johansson E, et al. Anovulatory, inadequate luteal phase and poor sperm penetration in cervical mucus during prolonged use of Norplant implants. Contraception 1985; 31: 261–73
   PubMed Web of Science ®Google Scholar
• Croxatto HB, Díaz S, Salvatierra AM, et al. Treatment with Norplant subdermal implants inhibits sperm penetration through cervical mucus in vitro. Contraception 1987; 36: 193–201
   PubMed Web of Science ®Google Scholar
• Croxatto HB, Mäkäräinen L. The pharmacodynamics and efficacy of Implanon®. An overview of the data. Contraception 1998; 58(Suppl 6): 91S–98S
   PubMed Web of Science ®Google Scholar
• Davies GC, Li XF, Newton JR, et al. Release characteristics, ovarian activity and menstrual bleeding pattern with a single contraceptive implant releasing 3-keto-desogestrel. Contraception 1993; 47: 251–61
   PubMed Web of Science ®Google Scholar
• Trussell J, Hatcher RA, Cates W Jr, et al. Contraceptive failure in the United States: an update. Stud Fam Plann 1990; 21: 51–4
   PubMed Web of Science ®Google Scholar
• Grubb GS, Moore D, Anderson NG. Pre-introductory clinical trials of Norplant® implants: a comparison of seventeen countries' experience. Contraception 1995; 52: 287–96
   PubMed Web of Science ®Google Scholar
• Sivin I. Contraception with Norplant® implants. Hum Reprod 1994; 9: 1818–26
   PubMed Web of Science ®Google Scholar
• Sivin I, Viegas O, Campodonico I, et al. Clinical performance of a new two-rod levonorgestrel contraceptive implant: a three-year randomized study with Norplant® implants as controls. Contraception 1997; 55: 73–80
   PubMed Web of Science ®Google Scholar
• Sivin I, Lähteenmäki P, Mishell DR, et al. First week drug concentrations in women with levonorgestrel rod or Norplant® capsule implants. Contraception 1997; 56: 317–21
   PubMed Web of Science ®Google Scholar
• Sivin I, Lähteenmäki P, Ranta S, et al. Levonorgestrel concentrations during use of levonorgestrel rod (LNG ROD) implants. Contraception 1997; 55: 81–5
   PubMed Web of Science ®Google Scholar
• Tmssell J, Leveque JA, Koenig JD, et al. The economic value of contraception: a comparison of 15 methods. Am J Pub Health 1995; 85: 494–503
   PubMed Web of Science ®Google Scholar
• Landgren B-M, Diczfalusy E. Hormonal effects of the 300 μg norethisterone (NET) minipill. 1. Daily steroid levels in 43 subjects during a pretreatment cycle and during the second month of NET administration. Contraception 1980; 21: 87–113
   PubMed Web of Science ®Google Scholar
• Kirton KT, Cornette JC. Return of ovulatory cyclicity following an intramuscular injection of medroxyprogesterone acetate (Provera). Contraception 1974; 10: 39–45
   PubMed Web of Science ®Google Scholar
• Kuhl H, Jung-Hoffmann C, Heidt F. Serum levels of 3-keto-desogestrel and SHBG during 12 cycles of treatment with 30 μg ethinylestradiol and 150 μg desogestrel. Contraception 1988; 38: 381–90
   PubMed Web of Science ®Google Scholar
• Mishell DR, Kharma KM, Thorneycroft IH, et al. Estrogenic activity in women receiving an injectable progestogen for contraception. Am J Obstet Gynecol 1972; 113: 372–6
   PubMed Web of Science ®Google Scholar
• Alvarez F, Brache V, Tejada AS, et al. Abnormal endocrine profile among women with confirmed or presumed ovulation during long-tenn Norplant® use. Contraception 1986; 33: 111–19
   PubMed Web of Science ®Google Scholar
• Faundes A, Brach EV, Tejeda AS, et al. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants. Fertil Steril 1991; 56: 27–31
   PubMed Web of Science ®Google Scholar
• Alvarez-Sanchez F, Brache V, Faundes A. The clinical performance of Norplant® implants over time: a comparison of two cohorts. Stud Fam Plann 1988; 19: 118–21
   PubMed Web of Science ®Google Scholar
• Brache V, Alvarez-Sanchez F, Faundes A, et al. Ovarian endocrine function through five years of continuous treatment with Norplant subdermal contraceptive implants. Contraception 1990; 41: 169–77
   PubMed Web of Science ®Google Scholar
• Díaz S, Schiappacasse V, Pavez M, et al. Clinical trial with Nestorone subdermal contraceptive implants. Contraception 1999; 51: 33–8
   Google Scholar
• Moore DE, Roy S, Stanczyk FZ, et al. Bleeding and serum d-norgestrel, estradiol and progesterone patterns in women using d-norgestrel subdermal polysiloxane capsules for contraception. Contraception 1978; 17: 315–28
   PubMed Web of Science ®Google Scholar
• Coelingh Bennink HJT. The pharmacokinetics and pharmacodynamics of Implanon®, a single-rod etonogestrel female contraceptive implant. Eur J Contracept Reprod Health Care 2000; 5(Suppl 2): 12–20
   PubMedGoogle Scholar
• Beerthuizen R, van Beek A, Massai A, Mäkäräinen L, Hout J, Bennink HC. Bone mineral density during long-term use of the progestagen contraceptive implant Implanon compared to a non-hormonal method of contraception. Hum Reprod 2000; 15: 118–22
   PubMed Web of Science ®Google Scholar
• Mascarenhas L, van Beek A, Coelingh Bennink H, et al. Twenty-four month comparison of apolipoproteins A-I, A-II, and B in contraceptive implants users (Norplant® and Implanon®) in Birmingham, United Kingdom. Contraception 1998; 58: 215–19
   PubMed Web of Science ®Google Scholar
• Sivin I. International experience with Norplant® and Norplant—2® contraceptives. Stud Fam Plann 1988; 19: 81–94
   PubMed Web of Science ®Google Scholar
• Croxatto HB, Díaz S, Pavey M, et al. Clearance of LNG from the circulation after removal of Norplant. Contraception 1988; 38: 509–23
   PubMed Web of Science ®Google Scholar
• Sivin I, Mishell DR Jr, Darney P, et al. Levonorgestrel capsule implants in the United States: a 5-year study. Obstet Gynecol 1998; 92: 337–44
   PubMed Web of Science ®Google Scholar
• Zieman M, Klaisle C, Walker D, et al. Instruments versus fingers for removing contraceptive implants (Norplant®). J Gynecol Tech 1997; 3: 213–17
   Google Scholar
• Lantz A, Nosher JL, Pasquale S, et al. Ultrasound characteristics of subdennally implanted Implanon™ contraceptive rods. Contraception 1997; 56: 323–7
   PubMed Web of Science ®Google Scholar
• Darney PD, Klaisle C, Walker DM. The ‘pop-out’ method of Norplant removal. Adv Contracept 1992; 8: 188
   Google Scholar
• Affandi B. An integrated analysis of vaginal bleeding patterns in clinical trials of Implanon®. Contraception 1998; 58(Suppl 6): 99S–107S
   PubMed Web of Science ®Google Scholar
• Díaz S, Faundes A, Olmos P, et al. Bleeding complaints during the first year of Norplant® implants use and their impact on removal rate. Contraception 1996; 53: 91–5
   PubMed Web of Science ®Google Scholar
• Schwallie PC. Experience with Depo-Provera as an injectable contraceptive. J Reprod Med 1974; 13: 113–17
   PubMed Web of Science ®Google Scholar
• Bhakshee K, Chatterjee P, Dhall GI, et al. Phase III clinical trial with Norplant®II (two covered rods). Report of five years of use. Contraception 1993; 48: 120–32
   PubMed Web of Science ®Google Scholar
• Lee TY, Yang YS, Tseng LH, et al. Norplant 2 subdermal contraceptive system: experience in Taiwan. J Formos Med Assoc 1993; 92: 446–50
   PubMedGoogle Scholar
• Belsey EM, Machin D, d'Arcangues C. The analysis of vaginal bleeding patterns induced by fertility regulating methods. Contraception 1986; 34: 253–60
   PubMed Web of Science ®Google Scholar
• Belsey EM, Farley TMM. The analysis of menstrual bleeding patterns: a review. Contraception 1988; 38: 129–56
   PubMed Web of Science ®Google Scholar
• Darney PD, Atkinson E, Tanner S, et al. Acceptance and perceptions of Norplant among users in San Francisco, USA. Stud Farn Plann 1990; 21: 152–60
   PubMed Web of Science ®Google Scholar
• Davie JE, Walling MR, Ashton Mansour DJ, et al. Impact of patient counselling on acceptance of the levonorgestrel implant contraceptive in the United Kingdom. Clin Ther 1996; 18: 150–9
   PubMed Web of Science ®Google Scholar
• Barnhart KT, Coutinho E, Furman I, et al. Changes in the menstrual bleeding of users of a subdermal contraceptive implant of nomegestrol acetate (Uniplant) do not influence sexual frequency, sexual desire, or sexual enjoyment. Fertil Steril 1997; 67: 244–9
   PubMed Web of Science ®Google Scholar
• Peralta O, Pavez M, Díaz S. Patologia anexial no inflamatoria durante el uso de implantes de levonorgestrel o dispositivos intrauterinos. Rev Chil Obstet Ginecol 1990; 55: 231–7
   Google Scholar
• McCann MF, Potter LS. Progestin-only oral contraception: a comprehensive review. Contraception 1994; 50 (6 Suppl 1): S1–S195
   PubMed Web of Science ®Google Scholar